GLP-1 drugs have garnered extensive media coverage and celebrity endorsements over the past year for their ability to drive weight loss. With more than 73% of adults in the US considered overweight or obese, millions taking GLP-1s, and head-to-head randomized clinical trials still being more than a year away, understanding the real-world effectiveness of these drugs is crucial. Truveta Research recently conducted a ground-breaking comparative effectiveness study using timely real-world data.

This webinar highlights results of a real-world GLP-1 comparative effectiveness study and the impact of timely and representative RWD in assessing performance of new therapies.